AUSTIN, TX — (Marketwire) — 02/09/11 — SmallCapVoice.com, Inc. announced today that a new audio interview featuring, Total Nutraceutical Solutions, Inc. (TNS) TNUS is now available. The interview can be heard at http://smallcapvoice.com/blog/2-8-11-audio-interview-with-total-nutraceutical-solutions-inc-otcbb-tnus
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and investor information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
About Ergo-D Traum™
Ergo-D Traum™ is a whole food proprietary formulation (patent pending) that uniquely combines mushrooms and phytonutrients to combat inflammation. This innovative whole food contains some of the most potent antioxidants and bionutrients found in nature. These very powerful natural antioxidants and bionutrients, Ergothioneine, vitamin D2 and beta glucans, have the potential to neutralize free radicals and suppress or prevent chronic inflammation.
Well-known medical institutions, such as Johns Hopkins School of Medicine, Mayo clinic and Oxford University, to name a few, are emphasizing the important roles played by these potent natural antioxidants in the prevention and control of inflammation and associated medical conditions.
About Total Nutraceutical Solutions, Inc.
TNS, a global biotechnology leader in whole food mushroom research and development focuses on discovering, formulating and marketing products composed primarily of organic, natural whole mushroom foods containing bioactive nutrients such as L-Ergothioneine and vitamin D, with potential health benefits. Our scientific strategy is to specialize in the development of production and analytic technologies for food and nutritional supplements mainly composed of mushrooms and their mycelial biomasses. Novel clinical models and biomarkers are used to show nutritional and clinical efficacy of our products. In addition to our novel preventative health care formulations and nutritional approaches for a wide variety of human conditions and illnesses, we are also involved in the development, acquisition and ownership of breakthrough nutritional tools and products in the fields of animal husbandry and livestock feeds.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Total Nutraceutical Solutions (TNS), Inc., with the Securities and Exchange Commission. Further information on risks faced by TNS are detailed in the Form 10-K for the year ended December 31, 2009, and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. TNS does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contact:
Roberta Matta
509-427-5132
TotalNutraceutical.com
Contact for SmallCapVoice.com:
Stuart T. Smith
512-267-2430
info@smallcapvoice.com
Source: Marketwire (February 9, 2011 – 8:00 AM EST)
Related posts
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
